Dr Clarisse Ganier

Dr Clarisse Ganier joined the Center of Gene Therapy and Regenerative Medicine in King's College London as a Post Doctoral Research Associate to work in Professor Fiona M. Watt lab and Dr Magnus Lynch lab.

She is part of the Human Cell Atlas initiative – an international collaborative effort to map all cell types within the human body –  to generate a comprehensive Skin Cell Atlas. Single cell genomics has revealed that many skin cell types can be subdivided into discrete subpopulations however the spatial relationships of these cell populations and how they differ qualitatively and across anatomical sites and in cutaneous malignancy remain poorly understood. To address these questions, she have combined single cell genomics with spatial transcriptomic approaches (spatial transcriptomics and in situ sequencing) to decipher these relationships in both healthy skin and skin cancer.

Qualifications:

• PhD in Human Genetics, Paris Descartes University, France, 2018
• MSc in Genetics, Paris Diderot University, France & La Sapienza University, Roma, Italy (double degree), 2015
• European Magistere of Genetics, 2015

Latest Publications

• 'Fibroblast Heterogeneity in Healthy and Wounded Skin'. Cold Spring Harb Perpect Biol. 2022 Jun 6;14a041238. doi:10.1101/cshperpect.a041238. Online ahead of print. PMID:35667795
• 'Gradient boosting approaches can outperform logistic regression for risk prediction in cutaneous allergy.' Cunningham L, Ganier C, Ferguson F, White IR, Watt FM, McFadden J, Lynch MD. Contact Dermatitis.2021 Nov 23. doi: 10.1111/cod.14011. Online ahead of print. PMID: 34812539 [PubMed]
• 'Angiotensin-Converting Enzyme 2 Expression Is Detectable in Keratinocytes, Cutaneous Appendages, and Blood Vessels by Multiplex RNA in Situ Hybridization.' Ganier C, Harun N, Peplow I, Du-Harpur X, Arthurs C, Watt FM, Lynch MD. Adv Skin Wound Care.2022 Jan 26. doi: 10.1097/01.ASW.0000819776.56007.18. Online ahead of print. PMID: 35085122 [PubMed]
• 'Applications and future directions for optical coherence tomography in dermatology.' Wan B*, Ganier C*, Du-Harpur X, Harun N, Watt FM, Patalay R, Lynch MD. Br J Dermatol.2020 Sep 24. doi: 10.1111/bjd.19553. PMID: 32974943 [PubMed]
• 'Clinically-relevant vulnerabilities of deep machine learning systems for skin cancer diagnosis.' Du-Harpur X*, Arthurs C*, Ganier C, Woolf R, Laftah Z, Lakhan M, Salam A, Wan B, Watt FM, Luscombe NM, Lynch MD. J Invest Dermatol.2020 Sep 12:S0022-202X(20)32056-X. doi: 10.1016/j.jid.2020.07.034. PMID: 32931808 [PubMed]
• 'Emerging Technologies in Scar Management: The Role of Allogeneic Cells.' Ganier C. and Gaucher S. In Textbook on Scar Management: State of the Art Management and Emerging Technologies. 2020 Dec. Edited by Luc Téot, Thomas A. Mustoe, Esther Middelkoop, and Gerd G. Gauglitz, 451–55. Cham: Springer International Publishing.
• 'Ethical Considerations: Scar Management.' Ganier C. and Gaucher S. In Textbook on Scar Management: State of the Art Management and Emerging Technologies. 2020 Dec. Edited by Luc Téot, Thomas A. Mustoe, Esther Middelkoop, and Gerd G. Gauglitz, 179–81. Cham: Springer International Publishing.
• 'Gene trial: patient preselection outcomes for the European GENEGRAFT ex vivo phase I/II gene therapy trial for recessive dystrophic epidermolysis bullosa.' Gaucher S., Lwin SM., Titeux M., Abdul-Wahab A., Pironon N., Izmiryan A., Miskinyte S., Ganier C., Duchatelet S., Mellerio JE., Bourrat E., McGrath JA., Hovnanian A. EB Br J Dermatol.2020 Mar;182(3):794-797 PMID: 31557321 [PubMed]
• 'Ex vivo COL7A1 correction for Recessive Dystrophic Epidermolysis Bullosa using CRISPR/Cas9 and Homology Directed Repair.' Izmiryan A., Ganier C., Bovolenta M., Schmitt A., Mavilio F. and Hovnanian A. Mol Ther Nucleic Acids.2018 Sep 7;12:554-567 PMID: 30195791 [PubMed]
• 'Intradermal injection of bone marrow-MSC corrects Recessive Dystrophic Epidermolysis Bullosa in a xenograft model.' Ganier C., Titeux M., Gaucher S., Peltzer J., Le Lorc'h M., Lataillade JJ., Ishida-Yamamoto A., and Hovnanian A. J Invest Dermatol.2018 Jul 11. pii: S0022-202X(18)31965-1 PMID: 29758284 [PubMed]
• 'Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.' Jacków J., Titeux M., Portier S., Charbonnier S., Ganier C., Gaucher S., and Hovnanian A. Invest. Dermatol.2016 Jul;136(7):1346-54 PMID: 26994967 [PubMed]